|
|
|
|
|
|
|
|
|
|
Note: this NCI article does not include ovarian cancer but does include platinum/taxane combination therapies (Carboplatin, Taxol); the JAMA paper most likely included ovarian cancer, however, the full text of the article is pay-per-view ($$$)
"The results were published February 2, 2011, in JAMA.":
JAMA abstract:
Treatment-Related Mortality With Bevacizumab in Cancer Patients
A Meta-analysis
"The overall incidence of FAEs (fatal adverse events) with bevacizumab was 2.5%."
Fine information, many thanks to the author. It is puzzling to me now, but in general, the usefulness and significance is overwhelming. Very much thanks again and best of luck!
ReplyDelete